Cargando…

Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis

BACKGROUND: Combining testosterone and phosphodiesterase 5 inhibitors (PDE5-Is) has become increasingly common in the treatment of men with erectile dysfunction (ED) and low testosterone levels, but combination therapy involving PDE5-Is and testosterone is highly debated, with strong reasons for and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Jun, Zhang, Wei, Ou, Ningjing, Song, Yuxuan, Kang, Jiaqi, Liang, Zhen, Hu, Rui, Yang, Yongjiao, Liu, Xiaoqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215032/ https://www.ncbi.nlm.nih.gov/pubmed/32420164 http://dx.doi.org/10.21037/tau.2020.01.13

Ejemplares similares

The Effect of Testosterone Replacement Therapy on Penile Hemodynamics in Hypogonadal Men With Erectile Dysfunction, Having Veno-Occlusive Dysfunction
por: Efesoy, Ozan, et al.
Publicado: (2018)

Testosterone Deficiency with Erectile Dysfunction in Mongolian Men
por: Naidan, Nansalmaa, et al.
Publicado: (2013)

Phosphodiesterase Type 5 Inhibitors and Risk of Skin Cancers in Men: A Meta-Analysis and Trial Sequential Analysis Involving 7,479,852 Subjects
por: Lu, Yi Patrick., et al.
Publicado: (2021)

The triad of erectile dysfunction, hypogonadism and the metabolic syndrome
por: Shabsigh, R, et al.
Publicado: (2008)

Hypogonadism and erectile dysfunction as harbingers of systemic disease
por: Chiles, Kelly A.
Publicado: (2016)

Adherence to Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction in Long-Term Users: How Do Men Use the Inhibitors?
por: Carvalheira, Ana, et al.
Publicado: (2014)

Hypogonadism and erectile dysfunction in myotonic dystrophy type 1
por: PERIC, STOJAN, et al.
Publicado: (2013)

New treatment possibilities for postcovid hypogonadism and erectile dysfunction
por: Knigavko, Prof. Oleksandr V., et al.
Publicado: (2022)

New treatment possibilities for postcovid hypogonadism and erectile dysfunction.
por: Knigavko, Oleksandr V., et al.
Publicado: (2022)

Development and Validation of a Nomogram to Predict Lymph Node Metastasis in Patients With T1 High-Grade Urothelial Carcinoma of the Bladder
por: Ou, Ningjing, et al.
Publicado: (2020)

Is there a relationship between the severity of erectile dysfunction and the comorbidity profile in men with late onset hypogonadism?
por: Yassin, Aksam A., et al.
Publicado: (2015)

Accuracy of multiparametric magnetic resonance imaging for diagnosing prostate Cancer: a systematic review and meta-analysis
por: Zhen, Liang, et al.
Publicado: (2019)

Phosphodiesterase type 5 inhibitors for the treatment of post-nerve sparing radical prostatectomy erectile dysfunction in men
por: Li, Jinhong, et al.
Publicado: (2014)

Testosterone Is Associated with Erectile Dysfunction: A Cross-Sectional Study in Chinese Men
por: Liao, Ming, et al.
Publicado: (2012)

Frequency of Hypogonadism and Erectile Dysfunction in Type-II Diabetic Patients
por: Mushtaq, Samsam, et al.
Publicado: (2018)

Depression, testosterone concentration, sexual dysfunction and methadone use among men with hypogonadism and HIV infection
por: Amini Lari, Mahmood, et al.
Publicado: (2012)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction
por: Smith-Harrison, L.I., et al.
Publicado: (2016)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
por: Moschos, Marilita M, et al.
Publicado: (2016)

Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
por: Savas, Murat, et al.
Publicado: (2010)

Testosterone Replacement Therapy and Bone Mineral Density in Men with Hypogonadism
por: Kim, Se Hwa
Publicado: (2014)

Cognitive effects of testosterone and finasteride administration in older hypogonadal men
por: Borst, Stephen E, et al.
Publicado: (2014)

Testosterone versus clomiphene citrate in managing symptoms of hypogonadism in men
por: Dadhich, Pranav, et al.
Publicado: (2017)

Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
por: Ide, Veerle, et al.
Publicado: (2020)

PMON260 Cost-Effectiveness of Testosterone Treatment for Men with Hypogonadism
por: Jayasena, Channa, et al.
Publicado: (2022)

The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients
por: Lu, Yi, et al.
Publicado: (2020)

Testosterone therapy and bone quality in men with diabetes and hypogonadism: Study design and protocol
por: Russo, Vittoria, et al.
Publicado: (2021)

The effects of a low carbohydrate diet on erectile function and serum testosterone levels in hypogonadal men with metabolic syndrome: a randomized clinical trial
por: da Silva Schmitt, Caio, et al.
Publicado: (2023)

When is a varicocele repair indicated: the dilemma of hypogonadism and erectile dysfunction?
por: Dabaja, Ali A, et al.
Publicado: (2016)

A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men
por: Swerdloff, Ronald S, et al.
Publicado: (2020)

Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study
por: Rosenberg, M T, et al.
Publicado: (2009)

Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men
por: Shankara Narayana, Nandini, et al.
Publicado: (2021)

Long-term testosterone replacement therapy reduces fatigue in men with hypogonadism
por: de Almeida Ferreira, Maurício, et al.
Publicado: (2022)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
por: Konstantinopoulos, Angelis, et al.
Publicado: (2007)

Long-term Opioids Linked to Hypogonadism and the Role of Testosterone Supplementation Therapy
por: Marudhai, Suganya, et al.
Publicado: (2020)

Hypogonadotropic hypogonadism in human immunodeficiency virus-infected men: uncommonly low testosterone levels
por: Gomes, Ana Coelho, et al.
Publicado: (2017)

Testosterone replacement in male hypogonadism
por: Kalra, Sanjay, et al.
Publicado: (2010)

Gene Expression Profiles Identified Novel Urine Biomarkers for Diagnosis and Prognosis of High-Grade Bladder Urothelial Carcinoma
por: Song, Yuxuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_adr782a0b4351pirss9vp4220t